Cargando…

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis

BACKGROUND: Brain metastases (BMs) are frequent events in patients with HER2-positive metastatic breast cancer (MBC) and are associated with poor prognosis. Small-molecule anti-HER2 tyrosine kinase inhibitors (TKIs) are promising agents for the treatment of BM. In this study, we assess the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nader-Marta, G., Martins-Branco, D., Agostinetto, E., Bruzzone, M., Ceppi, M., Danielli, L., Lambertini, M., Kotecki, N., Awada, A., de Azambuja, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160675/ https://www.ncbi.nlm.nih.gov/pubmed/35653982 http://dx.doi.org/10.1016/j.esmoop.2022.100501

Ejemplares similares

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
por: Agostinetto, E., et al.
Publicado: (2021)

Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
por: Molinelli, C., et al.
Publicado: (2023)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
por: Caparica, R., et al.
Publicado: (2021)

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Poggio, Francesca, et al.
Publicado: (2018)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis
por: Yu, Yushuai, et al.
Publicado: (2023)

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
por: Tagliamento, Marco, et al.
Publicado: (2021)

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives
por: Kotecki, Nuria, et al.
Publicado: (2018)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

The Exciting New Field of HER2-Low Breast Cancer Treatment
por: Eiger, Daniel, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
por: Nader-Marta, Guilherme, et al.
Publicado: (2023)

Twenty years of anti-HER2 therapy-associated cardiotoxicity
por: Pondé, Noam F, et al.
Publicado: (2016)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
por: Griffin, Nathan, et al.
Publicado: (2020)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis
por: Caparica, Rafael, et al.
Publicado: (2021)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody–Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis
por: Wang, Yan, et al.
Publicado: (2022)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

How we treat HER2-positive brain metastases
por: Stavrou, E., et al.
Publicado: (2021)

Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases
por: Li, Jing, et al.
Publicado: (2022)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
por: Conlon, Neil T., et al.
Publicado: (2021)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_us7qbu0gahj0aaekeo1sonkqm2